| Association of survival and immune-related biomarkers with immunotherapy in patients with non–small cell lung cancer: A meta-analysis and individual patient–level analysis Y Yu, D Zeng, Q Ou, S Liu, A Li, Y Chen, D Lin, Q Gao, H Zhou, W Liao, ... JAMA network open 2 (7), e196879-e196879, 2019 | 201 | 2019 |
| Development and validation of a preoperative magnetic resonance imaging radiomics–based signature to predict axillary lymph node metastasis and disease-free survival in … Y Yu, Y Tan, C Xie, Q Hu, J Ouyang, Y Chen, Y Gu, A Li, N Lu, Z He, ... JAMA network open 3 (12), e2028086-e2028086, 2020 | 168 | 2020 |
| Magnetic resonance imaging radiomics predicts preoperative axillary lymph node metastasis to support surgical decisions and is associated with tumor microenvironment in … Y Yu, Z He, J Ouyang, Y Tan, Y Chen, Y Gu, L Mao, W Ren, J Wang, L Lin, ... EBioMedicine 69, 2021 | 123 | 2021 |
| Association of long noncoding RNA biomarkers with clinical immune subtype and prediction of immunotherapy response in patients with cancer Y Yu, W Zhang, A Li, Y Chen, Q Ou, Z He, Y Zhang, R Liu, H Yao, E Song JAMA network open 3 (4), e202149-e202149, 2020 | 76 | 2020 |
| Clinical evidence for association of neoadjuvant chemotherapy or chemoradiotherapy with efficacy and safety in patients with resectable esophageal carcinoma (NewEC study) HY Zhou, SP Zheng, AL Li, QL Gao, QY Ou, YJ Chen, ST Wu, DG Lin, ... EClinicalMedicine 24, 2020 | 23 | 2020 |
| Association of survival and genomic mutation signature with immunotherapy in patients with hepatocellular carcinoma Q Ou, Y Yu, A Li, J Chen, T Yu, X Xu, X Xie, Y Chen, D Lin, Q Zeng, ... Annals of Translational Medicine 8 (5), 2020 | 20 | 2020 |
| Association of immune checkpoint inhibitor therapy with survival in patients with cancers with MUC16 variants Y Yu, D Lin, A Li, Y Chen, Q Ou, H Hu, H Yao JAMA Network Open 3 (6), e205837-e205837, 2020 | 15 | 2020 |
| Association of immune checkpoint inhibitor with survival in patients with cancers with protein tyrosine phosphatase receptor T mutation Z He, A Li, D Lin, Y Gu, Y Chen, Q Ou, L Li, H Yao, Y Yu Clinical and Translational Medicine 10 (6), 2020 | 7 | 2020 |
| Joint association of patients’ sex and PD‐L1 expression with overall survival benefits and tumor‐immune microenvironment in immune checkpoint inhibitors for cancers A Li, Y Chen, W Zhang, H Zhong, Q Ou, Y Gu, J Xia, D Lin, T Fu, R Liu, ... Clinical and translational medicine 10 (2), 2020 | 7 | 2020 |
| STK11/LKB1-deficient phenotype rather than mutation diminishes immunotherapy efficacy and represents STING/type I interferon/CD8+ T-cell dysfunction in NSCLC A Li, Y Wang, Z Yu, Z Tan, L He, S Fu, M Shi, W Du, L Luo, Z Li, J Liu, ... Journal of Thoracic Oncology 18 (12), 1714-1730, 2023 | 5 | 2023 |
| Novel blood‐based tumor mutation algorithm and nomogram predict survival of immune checkpoint inhibitor in non‐small‐cell lung cancer: Results from two multicenter, randomized … Y Yu, Y Chen, A Li, Q Ou, Q Li, Y Gu, D Lin, W Zhang, J Wang, X Tang, ... Clinical and translational medicine 10 (2), 2020 | 3 | 2020 |
| Cuproptosis-related immune gene signature predicts clinical benefits from anti-PD-1/PD-L1 therapy in non-small-cell lung cancer L Luo, A Li, S Fu, W Du, LN He, X Zhang, Y Wang, Y Zhou, Y Yunpeng, ... Immunologic Research, 1-16, 2022 | 2 | 2022 |
| Efficacy and a novel clinicopathologic-genomic nomogram of atezolizumab in advanced non-small cell lung cancer (POPLAR and OAK): A combined analysis of two multicenter … Y Yu, Y Chen, A Li, Q Ou, Y Wang, W Ren, W Zhang, Y Tan, H Yao 2019 ASCO Annual Meeting 37, 2573-2573, 2019 | 2 | 2019 |
| Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis Y Zhou, A Li, H Yu, Y Wang, X Zhang, H Qiu, W Du, L Luo, S Fu, L Zhang, ... JAMA Network Open 7 (3), e241285-e241285, 2024 | 1 | 2024 |
| Tumor response assessment by measuring the single largest lesion per organ in advanced non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitor LN He, T Chen, S Fu, Y Jiang, X Zhang, C Chen, W Du, L Luo, A Li, ... Therapeutic Advances in Medical Oncology 15, 17588359231200463, 2023 | 1 | 2023 |
| Tumour microenvironment and radiomics landscape associated with survival and prediction of immunotherapy in patients with cancer W Zhang, A Li, Y Chen, Q Ou, W Ren, Z He, Y Yu, H Yao 2020 ESMO Immuno-Oncology Congress, S1423, 2020 | 1 | 2020 |
| Surrogate end points for overall survival in patients with advanced non-small-cell lung cancer in trials of immunotherapy. Q Ou, Y Yu, A Li, Y Chen, Y Wang, W Ren, C Li, H Yao 2019 ASCO Annual Meeting 37, e14122-e14122, 2019 | 1 | 2019 |
| Association of immune-related adverse events with immune checkpoint inhibitor efficacy in pancancer. Q Ou, Y Yu, H Zhong, A Li, Y Chen, HY Zhou, S Zheng, L Huang, H Yao 2019 ASCO Annual Meeting 37, e14087-e14087, 2019 | 1 | 2019 |
| The efficacy of adjuvant interferon, tumor vaccines and cellular immunotherapies in hepatocellular carcinoma. Q Ou, Y Yu, A Li, T Fu, Q Gao, X Xiao, B Luo 2018 ASCO Annual Meeting 36, e16125-e16125, 2018 | 1 | 2018 |
| Abstract LB266: AMG510-mediated inactivation of BCL-xL protein promotes Gasdermin-E-dependent pyroptosis in KRAS-G12C mutant non-small cell lung cancer L Luo, A Li, W Du, M Chen, JI Li, Y Zhou, L Zhang, S Hong 2024 AACR Annual Meeting, LB266-LB266, 2024 | | 2024 |
SHAODONG HONGSUN YAT-SEN UNIVERSITY CANCER CENTERVerified email at sysucc.org.cn
